Floatz logo

Veltuzumab

Diffuse Large B-Cell Lymphoma

Gilead Sciencesmonoclonal_antibodyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

253 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Veltuzumab is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
58 / 100
View asset →
CLLDormant
CCC
Indicative ·
55 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →